These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28467330)

  • 61. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
    Kane JS; Ford AC
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: a pilot study.
    Laghi L; Mastromarino P; Elisei W; Capobianco D; Zhu CL; Picchio M; Giorgetti G; Brandimarte G; Tursi A
    J Biol Regul Homeost Agents; 2018; 32(5):1421-1432. PubMed ID: 30574746
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review.
    Carabotti M; Annibale B; Severi C; Lahner E
    Nutrients; 2017 Feb; 9(2):. PubMed ID: 28230737
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
    Tursi A; Cassieri C; Colucci R; Elisei W; Picchio M; Brandimarte G
    J Gastrointestin Liver Dis; 2019 Dec; 28(suppl. 4):45-48. PubMed ID: 31930223
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
    Meyrat P; Safroneeva E; Schoepfer AM
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
    Brandimarte G; Tursi A
    Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort.
    Lahat A; Fidder HH; Ben-Horin S
    Therap Adv Gastroenterol; 2020; 13():1756284820913210. PubMed ID: 32523619
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of Diverticular Disease With Aminosalicylates: The Evidence.
    Barbara G; Cremon C; Barbaro MR; Bellacosa L; Stanghellini V
    J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S60-3. PubMed ID: 27622369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Management of diverticular disease: is there room for rifaximin?
    Papi C; Koch M; Capurso L
    Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
    Bajaj JS; Barbara G; DuPont HL; Mearin F; Gasbarrini A; Tack J
    Dig Liver Dis; 2018 Aug; 50(8):741-749. PubMed ID: 29807873
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Unmet needs in treatment of symptomatic uncomplicated diverticular disease and prevention of recurrent acute diverticulitis: a scoping review.
    Carabotti M; Cuomo R; Marasco G; Barbara G; Radaelli F; Annibale B
    Therap Adv Gastroenterol; 2024; 17():17562848241255297. PubMed ID: 38812706
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy.
    De Vincentis A; Santonico M; Del Chierico F; Altomare A; Marigliano B; Laudisio A; Reddel S; Grasso S; Zompanti A; Pennazza G; Putignani L; Guarino MPL; Cicala M; Antonelli Incalzi R
    Front Med (Lausanne); 2021; 8():655474. PubMed ID: 34350192
    [No Abstract]   [Full Text] [Related]  

  • 74. Increased
    Ponziani FR; Scaldaferri F; De Siena M; Mangiola F; Matteo MV; Pecere S; Petito V; Sterbini FP; Lopetuso LR; Masucci L; Cammarota G; Sanguinetti M; Gasbarrini A
    Benef Microbes; 2020 Oct; 11(6):519-525. PubMed ID: 32885687
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diverticulitis: new insights on the traditional point of view.
    Moubax K; Urbain D
    Acta Gastroenterol Belg; 2015; 78(1):38-48. PubMed ID: 26118576
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Updates in the understanding and management of diverticular disease.
    Eckmann JD; Shaukat A
    Curr Opin Gastroenterol; 2022 Jan; 38(1):48-54. PubMed ID: 34619712
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
    Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
    Cuomo R; Barbara G; Annibale B
    Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diverticulosis, Diverticulitis, and Diverticular Bleeding.
    Wan D; Krisko T
    Clin Geriatr Med; 2021 Feb; 37(1):141-154. PubMed ID: 33213768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.